BR9206156A - Oligonucleotídeo ou análogo de aligonucleotídeo processo de modular a expressão do gene H-RAS humano processo de detectar a presença do gene H-RAS em células ou em tecidos processo de detectar H-RAS ativado baseado na afinidade diferencial de oligonucleotídeos particulares por H-RAS ativado VS,tipo,processo de tratar condicões que surgem da ativacão do oncogene H-RAS - Google Patents

Oligonucleotídeo ou análogo de aligonucleotídeo processo de modular a expressão do gene H-RAS humano processo de detectar a presença do gene H-RAS em células ou em tecidos processo de detectar H-RAS ativado baseado na afinidade diferencial de oligonucleotídeos particulares por H-RAS ativado VS,tipo,processo de tratar condicões que surgem da ativacão do oncogene H-RAS

Info

Publication number: BR9206156A
Authority: BR; Brazil
Prior art keywords: ras; activated; detecting; oligonucleotide; gene
Prior art date: 1991-06-14

Application number

BR9206156A

Other languages

English (en)

Inventor

Brett P Monia

Susan M Freier

David J Ecker

Original Assignee

Isis Pharmaceuticals Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1991-06-14

Filing date

1992-06-11

Publication date

1995-10-17

1992-06-11 Application filed by Isis Pharmaceuticals Inc filed Critical Isis Pharmaceuticals Inc

1995-10-17 Publication of BR9206156A publication Critical patent/BR9206156A/pt

Links

108091034117 Oligonucleotide Proteins 0.000 title abstract 8
238000000034 method Methods 0.000 title abstract 5
JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 title abstract 2
101150012162 H-RAS gene Proteins 0.000 title 4
230000004913 activation Effects 0.000 title 1
108700042226 ras Genes Proteins 0.000 title 1
108020000948 Antisense Oligonucleotides Proteins 0.000 abstract 2
239000000074 antisense oligonucleotide Substances 0.000 abstract 2
238000012230 antisense oligonucleotides Methods 0.000 abstract 2
230000000295 complement effect Effects 0.000 abstract 2

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1135—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against oncogenes or tumor suppressor genes
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/82—Translation products from oncogenes
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/0004—Oxidoreductases (1.)
- C12N9/0069—Oxidoreductases (1.) acting on single donors with incorporation of molecular oxygen, i.e. oxygenases (1.13)
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/61—Fusion polypeptide containing an enzyme fusion for detection (lacZ, luciferase)
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/321—2'-O-R Modification
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/322—2'-R Modification
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/33—Chemical structure of the base
- C12N2310/333—Modified A
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/352—Nature of the modification linked to the nucleic acid via a carbon atom
- C12N2310/3521—Methyl
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/352—Nature of the modification linked to the nucleic acid via a carbon atom
- C12N2310/3527—Other alkyl chain
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/353—Nature of the modification linked to the nucleic acid via an atom other than carbon
- C12N2310/3533—Halogen
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/353—Nature of the modification linked to the nucleic acid via an atom other than carbon
- C12N2310/3535—Nitrogen
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
Genetics & Genomics (AREA)
Engineering & Computer Science (AREA)
Zoology (AREA)
Wood Science & Technology (AREA)
Bioinformatics & Cheminformatics (AREA)
Molecular Biology (AREA)
Biomedical Technology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
General Engineering & Computer Science (AREA)
Biotechnology (AREA)
Biochemistry (AREA)
General Health & Medical Sciences (AREA)
Microbiology (AREA)
Biophysics (AREA)
Oncology (AREA)
Physics & Mathematics (AREA)
Medicinal Chemistry (AREA)
Immunology (AREA)
Pathology (AREA)
Analytical Chemistry (AREA)
Gastroenterology & Hepatology (AREA)
Plant Pathology (AREA)
Hospice & Palliative Care (AREA)
Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Saccharide Compounds (AREA)

BR9206156A 1991-06-14 1992-06-11 Oligonucleotídeo ou análogo de aligonucleotídeo processo de modular a expressão do gene H-RAS humano processo de detectar a presença do gene H-RAS em células ou em tecidos processo de detectar H-RAS ativado baseado na afinidade diferencial de oligonucleotídeos particulares por H-RAS ativado VS,tipo,processo de tratar condicões que surgem da ativacão do oncogene H-RAS BR9206156A (pt)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US71519691A	1991-06-14	1991-06-14
PCT/US1992/005008 WO1992022651A1 (en)	1991-06-14	1992-06-11	Antisense oligonucleotide inhibition of the ras gene

Publications (1)

Publication Number	Publication Date
BR9206156A true BR9206156A (pt)	1995-10-17

Family

ID=24873033

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BR9206156A BR9206156A (pt)	1991-06-14	1992-06-11	Oligonucleotídeo ou análogo de aligonucleotídeo processo de modular a expressão do gene H-RAS humano processo de detectar a presença do gene H-RAS em células ou em tecidos processo de detectar H-RAS ativado baseado na afinidade diferencial de oligonucleotídeos particulares por H-RAS ativado VS,tipo,processo de tratar condicões que surgem da ativacão do oncogene H-RAS

Country Status (11)

Country	Link
US (1)	US5582972A (pt)
EP (1)	EP0590082B1 (pt)
JP (1)	JP2726754B2 (pt)
AT (1)	ATE186072T1 (pt)
AU (1)	AU672175B2 (pt)
BR (1)	BR9206156A (pt)
CA (1)	CA2111472A1 (pt)
DE (1)	DE69230223T2 (pt)
DK (1)	DK0590082T3 (pt)
ES (1)	ES2138972T3 (pt)
WO (1)	WO1992022651A1 (pt)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5872232A (en) *	1990-01-11	1999-02-16	Isis Pharmaceuticals Inc.	2'-O-modified oligonucleotides
US5859221A (en) *	1990-01-11	1999-01-12	Isis Pharmaceuticals, Inc.	2'-modified oligonucleotides
US6399754B1 (en)	1991-12-24	2002-06-04	Isis Pharmaceuticals, Inc.	Sugar modified oligonucleotides
US6005087A (en) *	1995-06-06	1999-12-21	Isis Pharmaceuticals, Inc.	2'-modified oligonucleotides
US5965722A (en) *	1991-05-21	1999-10-12	Isis Pharmaceuticals, Inc.	Antisense inhibition of ras gene with chimeric and alternating oligonucleotides
US7015315B1 (en)	1991-12-24	2006-03-21	Isis Pharmaceuticals, Inc.	Gapped oligonucleotides
US7119184B2 (en)	1991-08-12	2006-10-10	Isis Pharmaceuticals, Inc.	Oligonucleotides having A-DNA form and B-DNA form conformational geometry
US6369209B1 (en)	1999-05-03	2002-04-09	Isis Pharmaceuticals, Inc.	Oligonucleotides having A-DNA form and B-DNA form conformational geometry
US8153602B1 (en)	1991-11-19	2012-04-10	Isis Pharmaceuticals, Inc.	Composition and methods for the pulmonary delivery of nucleic acids
FI951601L (fi)	1992-10-05	1995-05-29	Isis Pharmaceuticals Inc	Rasgeenin antisens-oligonukleotidi-inhibitio
US6399297B1 (en) *	1998-10-06	2002-06-04	Isis Pharmaceuticals, Inc.	Antisense modulation of expression of tumor necrosis factor receptor-associated factors (TRAFs)
US5459037A (en) *	1993-11-12	1995-10-17	The Scripps Research Institute	Method for simultaneous identification of differentially expressed mRNAs and measurement of relative concentrations
FR2715847B1 (fr) *	1994-02-08	1996-04-12	Rhone Poulenc Rorer Sa	Composition contenant des acides nucléiques, préparation et utilisations.
FR2724935B1 (fr) *	1994-09-27	1996-12-20	Centre Nat Rech Scient	Compositions nanoparticulaires contenant des derives nucleotidiques, leur preparation et leur emploi en therapeutique
GB9519299D0 (en) *	1995-09-21	1995-11-22	Farrar Gwyneth J	Genetic strategy
EP0882061B1 (en)	1996-02-14	2004-05-19	Isis Pharmaceuticals, Inc.	Sugar-modified gapped oligonucleotides
US20030069195A1 (en) *	1996-03-01	2003-04-10	Farrar Gwenyth Jane	Suppression of polymorphic alleles
US8551970B2 (en) *	1996-04-02	2013-10-08	Optigen Patents Limited	Genetic suppression and replacement
GB9606961D0 (en) *	1996-04-02	1996-06-05	Farrar Gwyneth J	Genetic strategy III
US9096636B2 (en)	1996-06-06	2015-08-04	Isis Pharmaceuticals, Inc.	Chimeric oligomeric compounds and their use in gene modulation
US5898031A (en)	1996-06-06	1999-04-27	Isis Pharmaceuticals, Inc.	Oligoribonucleotides for cleaving RNA
US5885834A (en) *	1996-09-30	1999-03-23	Epstein; Paul M.	Antisense oligodeoxynucleotide against phosphodiesterase
US5978738A (en)	1997-02-13	1999-11-02	Anthony Brown	Severe weather detector and alarm
US6172209B1 (en)	1997-02-14	2001-01-09	Isis Pharmaceuticals Inc.	Aminooxy-modified oligonucleotides and methods for making same
US6127533A (en)	1997-02-14	2000-10-03	Isis Pharmaceuticals, Inc.	2'-O-aminooxy-modified oligonucleotides
US6576752B1 (en)	1997-02-14	2003-06-10	Isis Pharmaceuticals, Inc.	Aminooxy functionalized oligomers
WO1998050540A1 (en)	1997-05-05	1998-11-12	Hoechst Marion Roussel Deutschland Gmbh	MODIFIED ANTISENSE NUCLEOTIDES COMPLEMENTARY TO A SECTION OF THE HUMAN Ha-Ras GENE
US6083923A (en) *	1997-10-31	2000-07-04	Isis Pharmaceuticals Inc.	Liposomal oligonucleotide compositions for modulating RAS gene expression
CA2329252A1 (en)	1998-05-21	1999-11-25	Isis Pharmaceuticals Inc.	Compositions and methods for topical delivery of oligonucleotides
US6242589B1 (en)	1998-07-14	2001-06-05	Isis Pharmaceuticals, Inc.	Phosphorothioate oligonucleotides having modified internucleoside linkages
US6867294B1 (en)	1998-07-14	2005-03-15	Isis Pharmaceuticals, Inc.	Gapped oligomers having site specific chiral phosphorothioate internucleoside linkages
US6277967B1 (en)	1998-07-14	2001-08-21	Isis Pharmaceuticals, Inc.	Carbohydrate or 2′-modified oligonucleotides having alternating internucleoside linkages
AU5128799A (en) *	1998-07-24	2000-02-14	Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The	Pb 39, a gene dysregulated in prostate cancer, and uses thereof
US7226731B1 (en)	1998-07-24	2007-06-05	The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services	PB 39, a gene dysregulated in prostate cancer, and uses thereof
US6451524B1 (en) *	1998-11-25	2002-09-17	Isis Pharmaceuticals, Inc.	Identification of disease predictive nucleic acids
US6114517A (en) *	1998-12-10	2000-09-05	Isis Pharmaceuticals Inc.	Methods of modulating tumor necrosis factor α-induced expression of cell adhesion molecules
EP1152009B2 (en)	1999-02-12	2017-09-06	Daiichi Sankyo Company, Limited	Novel nucleosides and oligonucleotide analogues
JP4151751B2 (ja) *	1999-07-22	2008-09-17	第一三共株式会社	新規ビシクロヌクレオシド類縁体
US6147200A (en) *	1999-08-19	2000-11-14	Isis Pharmaceuticals, Inc.	2'-O-acetamido modified monomers and oligomers
US20040002083A1 (en) *	2002-01-29	2004-01-01	Ye Ding	Statistical algorithms for folding and target accessibility prediction and design of nucleic acids
AU2003290598A1 (en)	2002-11-05	2004-06-03	Isis Pharmaceuticals, Inc.	Modified oligonucleotides for use in rna interference
EP1578767A4 (en) *	2002-12-04	2008-01-09	Algos Therapeutics Inc	METHOD AND MATERIALS FOR MODULATING TRPM2
EP1592795A2 (en) *	2003-02-10	2005-11-09	Santaris Pharma A/S	Oligomeric compounds for the modulation of ras expression
US7713738B2 (en)	2003-02-10	2010-05-11	Enzon Pharmaceuticals, Inc.	Oligomeric compounds for the modulation of survivin expression
US8569474B2 (en)	2004-03-09	2013-10-29	Isis Pharmaceuticals, Inc.	Double stranded constructs comprising one or more short strands hybridized to a longer strand
US8394947B2 (en)	2004-06-03	2013-03-12	Isis Pharmaceuticals, Inc.	Positionally modified siRNA constructs
US7884086B2 (en)	2004-09-08	2011-02-08	Isis Pharmaceuticals, Inc.	Conjugates for use in hepatocyte free uptake assays
WO2006050732A2 (en)	2004-11-09	2006-05-18	Santaris Pharma A/S	Lna oligonucleotides and the treatment of cancer
KR101878501B1 (ko) *	2010-01-04	2018-08-07	큐알엔에이, 인크.	인터페론 조절 인자 8 (ｉｒｆ8)에 대한 자연 안티센스 전사체의 저해에 의한 인터페론 조절 인자 8 (ｉｒｆ8) 관련된 질환의 치료
US10758558B2 (en)	2015-02-13	2020-09-01	Translate Bio Ma, Inc.	Hybrid oligonucleotides and uses thereof
EP3368089B1 (en)	2015-10-26	2025-11-05	Translate Bio Ma, Inc.	Nanoparticle formulations for delivery of nucleic acid complexes

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5034506A (en) *	1985-03-15	1991-07-23	Anti-Gene Development Group	Uncharged morpholino-based polymers having achiral intersubunit linkages
US4871838A (en) *	1985-07-23	1989-10-03	The Board Of Rijks Universiteit Leiden	Probes and methods for detecting activated ras oncogenes
US5087617A (en) *	1989-02-15	1992-02-11	Board Of Regents, The University Of Texas System	Methods and compositions for treatment of cancer using oligonucleotides

1992
- 1992-06-11 DK DK92914930T patent/DK0590082T3/da active
- 1992-06-11 BR BR9206156A patent/BR9206156A/pt not_active Application Discontinuation
- 1992-06-11 EP EP92914930A patent/EP0590082B1/en not_active Expired - Lifetime
- 1992-06-11 WO PCT/US1992/005008 patent/WO1992022651A1/en not_active Ceased
- 1992-06-11 AU AU22497/92A patent/AU672175B2/en not_active Ceased
- 1992-06-11 ES ES92914930T patent/ES2138972T3/es not_active Expired - Lifetime
- 1992-06-11 DE DE69230223T patent/DE69230223T2/de not_active Expired - Fee Related
- 1992-06-11 CA CA002111472A patent/CA2111472A1/en not_active Abandoned
- 1992-06-11 JP JP5501052A patent/JP2726754B2/ja not_active Expired - Fee Related
- 1992-06-11 AT AT92914930T patent/ATE186072T1/de not_active IP Right Cessation
- 1992-12-14 US US07/990,303 patent/US5582972A/en not_active Expired - Lifetime

Also Published As

Publication number	Publication date
US5582972A (en)	1996-12-10
DE69230223D1 (de)	1999-12-02
AU672175B2 (en)	1996-09-26
ATE186072T1 (de)	1999-11-15
DK0590082T3 (da)	1999-11-08
JP2726754B2 (ja)	1998-03-11
CA2111472A1 (en)	1992-12-23
EP0590082A4 (en)	1995-04-12
JPH06504679A (ja)	1994-06-02
EP0590082A1 (en)	1994-04-06
WO1992022651A1 (en)	1992-12-23
AU2249792A (en)	1993-01-12
EP0590082B1 (en)	1999-10-27
ES2138972T3 (es)	2000-02-01
DE69230223T2 (de)	2000-02-17

Publication	Publication Date	Title
BR9206156A (pt)	1995-10-17	Oligonucleotídeo ou análogo de aligonucleotídeo processo de modular a expressão do gene H-RAS humano processo de detectar a presença do gene H-RAS em células ou em tecidos processo de detectar H-RAS ativado baseado na afinidade diferencial de oligonucleotídeos particulares por H-RAS ativado VS,tipo,processo de tratar condicões que surgem da ativacão do oncogene H-RAS
Svoboda et al.	1993	DNA repair by eukaryotic nucleotide excision nuclease. Removal of thymine dimer and psoralen monoadduct by HeLa cell-free extract and of thymine dimer by Xenopus laevis oocytes.
Branch et al.	1985	Ultraviolet light-induced crosslinking reveals a unique region of local tertiary structure in potato spindle tuber viroid and HeLa 5S RNA.
Mizrahi et al.	1985	Rate-limiting steps in the DNA polymerase I reaction pathway
BR9106440A (pt)	1993-05-18	Oligonucleotideo ou analogo de olifonucleotideo e processo para tratar um animal suspeito de ter uma doenca que se caracteriza pela expressao de gene tat de hiv
CO5601048A2 (es)	2006-01-31	Evento de algodon mon 88913 y composiciones y metodos para su deteccion
ATE132190T1 (de)	1996-01-15	Hemmung von htlv-iii durch exogene oligonukleotide
DE69433626D1 (de)	2004-04-22	N-2 substituierte purine
AU7487787A (en)	1987-12-22	Inhibition of htlv-iii by exogenous oligonucleotides
DE69109100D1 (de)	1995-05-24	Oligonukleotid-analoge.
DE69838449D1 (de)	2007-10-31	Aminooxy-modifizierte oligonukleotide
EP0549615A4 (en)	1997-08-27	Sugar modified oligonucleotides that detect and modulate gene expression
DK0919565T3 (da)	2004-02-16	Mærkede oligonukleotider
DE69521517D1 (de)	2001-08-02	Prodrug-oligonukleotide
Wickner et al.	1972	Deoxyribonucleic Acid Polymerase II of Escherichia coli: II. STUDIES OF THE TEMPLATE REQUIREMENTS AND THE STRUCTURE OF THE DEOXYRIBONUCLEIC ACID PRODUCT
BR9007892A (pt)	1992-09-29	Oligonucleotideo ou analogo de oligonucleotideo,processos para modular a expressao de um papilomavirus,para modular os efeitos de uma infeccao provocada por papilomavirus em um animal e para detectar a presenca ou ausencia de papilomavirus e estojo para detectar a presenca ou ausencia de papilomavirus em uma amostra
AR018099A1 (es)	2001-10-31	Metodo de bloqueo de sintesis de la 17beta-hidroxiesteroide dehidrogenasa del tipo 5 y metodo para interferir su expresion
BR0202064A (pt)	2003-04-22	Método para identificação de um peptìdeo artimicrobiano, peptìdeo antimicrobiano isolado, análogos dos peptìdeos, seus usos, molécula de ácido nucleico isolada, vetor de expressão, célula hospedeira, método para prevenir o crescimento, inibir o crescimento ou reduzir a viabilidade de um microorganismo e método de tratamento de um organismo infectado com um microorganismo patogênico
CA2146320A1 (en)	1994-04-14	Antisense oligonucleotide inhibition of the ras gene
BR9106752A (pt)	1993-08-17	Oligonucleotideo ou analogo de oligonucleotideo,processo para tratamento de uma infeccao por candida e processo para a modulacao da atividade de candida
DE3575730D1 (de)	1990-03-08	Modifizierte adeninegruppe enthaltende sonde, ihre herstellung und verwendungen.
Setlow	1980	DNA repair pathways
DE69430740D1 (de)	2002-07-11	ANTISENSE OLIGONNUKLEOTIDE DIE MIT DER mRNA CAP AKTIVITÄT INTERFERIEREN UND DIE TRANSLATION INHIBIEREN
ES2161736T3 (es)	2001-12-16	Oligonucleotidos para la deteccion de enterobacteriaceas.
Merigan et al.	1971	Molecular requirements for synthetic RNA to act in interferon stimulation

Legal Events

Date	Code	Title	Description
1995-12-19	FA1	Application withdrawn (art. 18(2))